Eha 2025 | multiple studies report encouraging data of olverembatinib in ph+ all

Rockville, md. and suzhou, china, june 15, 2025 (globe newswire) -- ascentage pharma (nasdaq: aapg; hkex: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that results from 13 studies of its core assets, including the novel drug olverembatinib (hqp1351) and the investigational eed inhibitor apg-5918, have been reported at the 2025 european hematology association (eha) annual congress.
AAPG Ratings Summary
AAPG Quant Ranking